
Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced robust demand-led growth for its molluscum contagiosum treatment, YCANTH®, during the first quarter of 2025. The company reported a …
Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH Read More